Tesamorelin + Ipamorelin 10mg Peptide

This combination vial pairs tesamorelin, a stabilised growth hormone releasing hormone analogue, with ipamorelin, a selective agonist at the growth hormone secretagogue receptor. Like the CJC-1295 and ipamorelin pairing, it engages the two distinct receptor systems that control growth hormone release from the pituitary somatotroph, so the constituents are complementary rather than redundant.

Tesamorelin is the full 44 residue GHRH sequence carrying a trans-3-hexenoyl group at the N-terminus. That acyl cap blocks dipeptidyl peptidase-4, which cleaves native GHRH at precisely the residue the receptor requires, so cleavage would destroy activity rather than merely shorten the molecule. Receptor activation signals through Gs and cyclic AMP, triggering both release and synthesis of growth hormone while leaving somatostatin tone and IGF-1 feedback intact.

Ipamorelin arrives at the same cell through the ghrelin receptor GHS-R1a, signalling through Gq and phospholipase C to raise intracellular calcium and release stored growth hormone. Its distinguishing property is selectivity across pituitary axes: it was characterised as releasing growth hormone without the adrenocorticotropic hormone and cortisol rises produced by the earlier GHRP compounds. The two arms therefore reach one secretory event by separate routes.

This blend is unusual in the catalogue because one of its components has a genuine marketing authorisation. Tesamorelin is approved in the United States for reduction of excess visceral abdominal fat in people with HIV and lipodystrophy. Ipamorelin has no approval anywhere and did not progress past clinical investigation.

That asymmetry is easy to misread in a blend's favour. An approved indication is approval for a specific population, a specific endpoint and a specific product, and it says nothing about the same molecule used for another purpose or combined with an unapproved one.

Nothing about tesamorelin's approval transfers to this vial. The trial evidence behind it was generated with tesamorelin alone in people with HIV-associated lipodystrophy, and the combination has never been studied in anyone.

The clinical result behind tesamorelin's approval is specific: growth hormone is preferentially lipolytic at visceral adipose depots, and raising endogenous growth hormone reduced visceral fat while leaving subcutaneous fat comparatively less affected. Visceral fat drains to the portal circulation and carries different metabolic associations from subcutaneous fat, which is why the distinction is clinically meaningful.

That is a materially different claim from the weight reduction reported for incretin agents, and reading across between them misrepresents both. They act on different tissue compartments through unrelated receptor systems.

Adding a growth hormone secretagogue to a GHRH analogue raises the drive on the same axis by a second route. Whether that translates into more of the compartment-selective effect, or into something else, is not established by any study.

Analytically this is the most comfortable combination in the catalogue. Tesamorelin is near 5,136 daltons and ipamorelin near 712, a separation of roughly 4,424 daltons. Nothing about either could be mistaken for the other or for a plausible impurity of the other, and a mass spectrum resolves the composition instantly.

The ratio is not disclosed on the listing, which remains the open question for this vial as for the others. Two species this far apart are straightforward to quantify separately against reference standards, so per-constituent quantification is an easy measurement to ask for here.

Tesamorelin is also by far the larger molecule, so a mass-based ratio and a molar ratio differ substantially. A vial containing equal masses contains roughly seven times as many ipamorelin molecules as tesamorelin molecules, which is worth knowing before interpreting any stated ratio.

Both constituents contain oxidation-sensitive features: tesamorelin has a methionine, and ipamorelin contains tryptophan-adjacent aromatic residues in its D-2-naphthylalanine and D-phenylalanine substitutions. Tesamorelin is the larger and more fragile molecule, and a blend is only as stable as its least stable component.

Ipamorelin's non-proteinogenic residues mean enzymatic sequencing behaves unusually on that constituent, and both are C-terminally amidated with free acids differing by one dalton. Neither carries a reactive group, so buffer composition is less critical here than for blends containing GHK-Cu or a maleimide.